Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | DUT | P33316 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 1/20 | 0.34 |
| ▸ | TYMP | P19971 | 1/20 | 0.34 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5083593 | 0.91 | DUT (0.38) | DUTTYMPCCNB2CDK1CCNB1 | |
| SCHEMBL5085981 | 0.85 | HPRT1 (0.37) | LMNASMN1; SMN2ADORA2ATP53MAPT | |
| SCHEMBL5080062 | 0.83 | CDK1 (0.45) | ADORA2ACCNB2CDK1CCNB1CDK2 | |
| SCHEMBL6055218 | 0.80 | CDK1 (0.39) | DUTTYMPCCNB2CDK1CCNB1 | |
| SCHEMBL5085944 | 0.80 | LMNA (0.42) | LMNASMN1; SMN2DUTCCNB2CDK1 | |
| SCHEMBL5082994 | 0.78 | ABL1 (0.42) | ADORA2ACCNB2CDK1CCNB1CDK2 | |
| SCHEMBL5080087 | 0.77 | ABL1 (0.42) | LMNASMN1; SMN2TP53MAPTCCNB2 | |
| SCHEMBL5083017 | 0.77 | ADORA1 (0.43) | ADORA2ATP53 | |
| SCHEMBL5082970 | 0.77 | NR2F2 (0.43) | ADORA2A | |
| SCHEMBL14175344 | 0.77 | CDK1 (0.42) | TP53TYMPCCNB2CDK1CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7388002-B2 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-06-17 | — | — | US | disclosed |
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060122391-A1 | Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases | POLR2H, NSUN2, POLR2E | LMNA 2297/4885SMN1; SMN2 655/4885ADORA2A 1427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.